NTLA Similar Chart Price Prediction
The price of NTLA is predicted to go up -10.53%, based on the high correlation periods with BRTX. The similarity of these two price pattern on the periods is 94.45%.
NTLA
BRTX
Down: -10.53%Similarity: 94.45%
NTLA Revenue Forecast
NTLA EPS Forecast
NTLA FAQs
What is NTLA revenue forecast for next quarter？
What is NTLA eps forecast for next quarter？
NTLA VS S&P500
Intellia's partnerships allow it to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.
Intellia's Crispr/Cas9 platform has the potential to develop highly efficacious and curative treatments for rare, genetic diseases with high unmet needs, which will likely lead to pricing power if approved.
We view the company's pipeline as possessing strengthening intangible assets and assign it a positive moat trend.
NTLA Analyst's Forecast
Joon Lee
Truist Securities
Strong Buy
2025-03-04
Price Target
$90 → $50
Upside
+449.75%
Truist analyst Joon Lee lowered the firm's price target on Intellia Therapeutics to $50 from $90 and keeps a Buy rating on the shares. Intellia's restructuring should help extend the company's operational runway into the first half of 2027, as NTLA-2002 is poised to be the historic first in vivo genome editing therapeutic to launch in 2027 for hereditary angioedema, the analyst tells investors in a research note. While the firm believes Intellia has a winning platform, it says it is headed in an increasingly competitive space, driving the firm to moderate its commercial outlook for nex-z in transthyretin amyloidosis.
Jay Olson
Oppenheimer
Buy
2025-01-13
Price Target
$60 → $40
Upside
+298.01%
Yanan Zhu
Wells Fargo
Buy
2025-01-10
Price Target
$70 → $60
Upside
+488.24%
